Brief: BioInvent Gets FDA Fast Track Designation For Bi-1808
29/04/2025 10:55
April 29 (Reuters) - BioInvent International AB BINV.ST: BIOINVENT RECEIVES FDA FAST TRACK DESIGNATION FOR BI-1808 FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA Source text: ID:nMFN1YMbBp Further company coverage: BINV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))